Jump to content



Recommended Posts

  • Replies 37
  • Created
  • Last Reply

Top Posters In This Topic

Any thoughts ?



Narhex Life Sciences - IPO expected to close 20th December 2004

The Narhex offer is still open and is now due to close 20th December 2004. The support for this stock has been huge and applications are still coming in. The Company can accept oversubscriptions of up to $4 million. Applications will be dealt with on a first-come first-served basis - so get them in ASAP!


Although speculative, this company has enormous upside. Aegis Research has valued Narhex at 34cents per share compared to the IPO offer price of 20cents per share.


Plain and simple, this is one of a few biotech companies that we have seen come to market so far progressed in its clinical trials and commercialisation strategies. They have completed Phase I and early Phase II clinical trials in humans with success and the company has signed agreements with one of the Chinese government's most powerful trading entities, China Shaanxi Machinery Import & Export Corp (CMC), to fund and organise the remaining clinical studies and then market and distribute the drug in China. The funding and organisation of clinical studies are two of the hardest milestones to achieve for any biotech company.



Drug test deal as Narhex joins ASX

Teresa Ooi

January 12, 2005


NARHEX Life Science - a biotech due to list on the stock exchange today - has signed a drug-testing deal with a US medical research centre.


The US National Institute of Allergy and Infectious Diseases will examine whether a Narhex drug that is being tested for the treatment of HIV/AIDS can also be applied to Hepatitis C and the SARS virus.


The deal with the Institute, based in Bethesda, Maryland, comes hot on the heels of Narhex's initial public offering, which raised more than $8 million when it closed on January 4.


The funds will be used to fast-track clinical tests of the company's AIDS drug, Nar 35 DG Prodrug, particularly in China.


Narhex chief executive John Majewski said the deal with the institute was an important step to explore the broader application of the drug to other infectious diseases, especially Hepatitis C, for which there is no vaccine.


"Clearly this agreement opens up a drug pipeline of potential new products for the company," Mr Majewski said.


"The company's recent IPO ... gives us sufficient funding to complete our clinical studies in China and nurture other drugs for infectious diseases ..."


The company's Nar DG 35 Prodrug has undergone Phase 1 trials in Australia and early Phase 11 clinical trials in Brazil.


According to broking firm Intersuisse, the biotechnology sector gained very little over 2004, but is set to improve this year.



Link to comment
Share on other sites

Hi all,


A dismal debut considering the pre listing hype.


Here's the link for the Aegis report along with another crop.





Aegis Report


Narhex is issuing new shares to raise necessary capital to fund further research and commercial development of Nar DG 35 Prodrug, an Australian developed Protease Inhibitor that has entered into human pilot clinical trials for the treatment of HIV/AIDS. Protease Inhibitors are now important components of modern multi-drug regimes which, when used appropriately, extend both the quality and duration of life of HIV-infected patients.


Early Phase I & II human clinical trials suggest that Nar DG 35 Prodrug may have advantages over the majority of Protease Inhibitors currently available on the market.


Nar DG 35 Prodrug has patents registered in major markets including China, USA, Canada, EU and Australia, protecting its intellectual property.


According to the latest UNAIDS 4th Global Report (June 2004), 38 million people are now living with HIV. Last year 2.9 million people died from AIDS and almost 5 million new cases were diagnosedÃÆâ€â„¢ÃƒÆ’ƒâ€Â ÃƒÆ’¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒ¢Ã¢â‚¬Å¾Ã‚¢ÃƒÆ’ƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚¢ÃƒÆ’Æâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒâ€¦Ã‚¡ÃƒÆ’‚¬Ãƒâ€Â¦ÃƒÆ’‚¡ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚¬ÃƒÆ’Æâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’â€Â¦ÃƒƒÂ¢Ãƒ¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…âہ“ the largest number in any one year since the epidemic began. The UNAIDS report says efforts need to be focussed in Asia, which it warns needs to act now to prevent ÃÆâ€â„¢ÃƒÆ’ƒâ€Â ÃƒÆ’¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒ¢Ã¢â‚¬Å¾Ã‚¢ÃƒÆ’ƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚¢ÃƒÆ’Æâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒâ€¦Ã‚¡ÃƒÆ’‚¬Ãƒâ€Â¦ÃƒÆ’‚¡ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚¬ÃƒÆ’Æâ€â„¢ÃƒÆ’ƒÂ¢Ãƒ¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’‚¦ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒâ€¦Ã‚¡ÃƒÆ’‚¬Ãƒâ€Â¦ÃƒÆ’¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒâ€¦Ã¢â‚¬Å“a full blown AIDS catastropheÃÆâ€â„¢ÃƒÆ’ƒâ€Â ÃƒÆ’¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒ¢Ã¢â‚¬Å¾Ã‚¢ÃƒÆ’ƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚¢ÃƒÆ’Æâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒâ€¦Ã‚¡ÃƒÆ’‚¬Ãƒâ€Â¦ÃƒÆ’‚¡ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚¬ÃƒÆ’Æâ€â„¢ÃƒÆ’ƒÂ¢Ãƒ¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚ÂÂ.


Narhex has signed an agreement with CMC (a government instrumentality controlled by the Chinese Ministry of Foreign Trade) for CMC Shaanxi to organise and fund clinical Phase II/III studies on Nar DG 35 Prodrug in China, to seek Chinese registration of this compound and to obtain an exclusive license to distribute and market Nar DG 35 Prodrug as an approved drug in China.




Link to comment
Share on other sites

In reply to: xmagx on Wednesday 12/01/05 03:48pm

not as good as i thought, however have been watching today, i'm interested in this one. the close came as a bit of a surprise !!! maybe an indication of things to come. good luck to those that hold, i may join u soon.

Link to comment
Share on other sites

Hi All,


Background on Narhex Life Sciences Limited.....








In 1990 Narhex Australia recruited Dr Damian Grobelny, a research expert in the highly specialised field of the chemistry of protease enzyme function, and embarked on a research project to develop new forms of Protease Inhibitors that were less toxic than those in development and could be made at lower cost. Working in conjunction with the Fairfield Infectious Diseases Laboratory, Dr Grobelny synthesised a number of compounds that were tested against HIV. Two of these compounds showed a high degree of activity in test tube systems.

Subsequently Nar DG 35 was selected as being the most promising of the two compounds, Nar DG 35 and Nar DG 43, and as a result was tested further, initially in animals and subsequently in human volunteers.

A new company, Narhex Life Sciences Limited (ÃÆâ€â„¢ÃƒÆ’ƒâ€Â ÃƒÆ’¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒ¢Ã¢â‚¬Å¾Ã‚¢ÃƒÆ’ƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚¢ÃƒÆ’Æâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒâ€¦Ã‚¡ÃƒÆ’‚¬Ãƒâ€Â¦ÃƒÆ’‚¡ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚¬ÃƒÆ’Æâ€â„¢ÃƒÆ’ƒÂ¢Ãƒ¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’‚¹ÃƒÆ’â€Â¦ÃƒƒÂ¢Ãƒ¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…âہ“NarhexÃÆâ€â„¢ÃƒÆ’ƒâ€Â ÃƒÆ’¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒ¢Ã¢â‚¬Å¾Ã‚¢ÃƒÆ’ƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚¢ÃƒÆ’Æâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒâ€¦Ã‚¡ÃƒÆ’‚¬Ãƒâ€Â¦ÃƒÆ’‚¡ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚¬ÃƒÆ’Æâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒâ€¦Ã‚¡ÃƒÆ’‚¬Ãƒâ€Â¦ÃƒÆ’‚¾ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚¢) was formed which through its wholly owned subsidiary, Narhex Limited, now holds the intellectual property in Nar DG 35. NarhexÃÆâ€â„¢ÃƒÆ’ƒâ€Â ÃƒÆ’¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒ¢Ã¢â‚¬Å¾Ã‚¢ÃƒÆ’ƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚¢ÃƒÆ’Æâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒâ€¦Ã‚¡ÃƒÆ’‚¬Ãƒâ€Â¦ÃƒÆ’‚¡ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚¬ÃƒÆ’Æâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒâ€¦Ã‚¡ÃƒÆ’‚¬Ãƒâ€Â¦ÃƒÆ’‚¾ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚¢s purpose is now to seek registration in China, and further develop Nar DG 35 through to commercialisation.

Narhex Life Sciences Limited

Narhex Life Sciences Limited was incorporated on 13th September 2000. On 13th March 2001, Narhex Life Sciences purchased Narhex Limited, a company which was incorporated in Hong Kong on 23rd June 1981. Narhex Limited is the owner of the intellectual property rights.

The sole activity of Narhex Limited will be, and has always been, to hold the intellectual property rights in the Technology.




Recent Milestones

Narhex Australia shareholders formed a new company Narhex Life Sciences Limited to advance the further development of Nar DG 35 Prodrug.

Rhodia ChiRex a European/US fine drug manufacturer was contracted to scale-up Nar DG 35 Prodrug to run further clinical studies.

2001 - 2002
Rhodia ChiRex acquired equity in Narhex Life Sciences Limited.

2002 - September 11th
Narhex was granted a patent in China for its protease inhibitors Nar DG 35 VIII and Nar DG 43a.

2002 - 2003
CMC Shaanxi conducted its due diligence on Narhex anti-HIV Drug discoveries.

2003 to date
Narhex had patents granted for its active and oral prodrug form of its protease inhibitors, for the most important markets. US, EU, Canada, Mexico, South Korea, Australia and Taiwan to name some of the most important markets.

2004 - February
Australian Government, through the Prime Minister, recognises the importance of Narhex DG 35 Prodrug and urged its further development.

2004 - May 19th
CMC Shaanxi signed heads of agreement with Narhex to aid it to develop Nar DG 35 Prodrug for China.

2004 - April 7th
Narhex was granted a patent in China for the prodrug form (oral delivery component) for its protease inhibitors Nar DG 35 VIII and Nar DG 43a.

Link to comment
Share on other sites

  • 2 weeks later...
  • 2 months later...
  • 8 months later...

Up 26.5% on Investsmart Newsletter.





Lets kick off the New Year with a stock pick. Though you may want to take it with a grain of salt since InvestSMART is a major shareholder of this company (shares are escrowed until Janurary 2007). Being a major shareholder puts us in a unique position of knowing a fair bit about this company and its potential. If nothing else, do your own research and watch this space carefully around mid February when we find out the results of their current clinical trials.


Narhex Life Sciences (ASX : NLS) is a drug development company that has developed a library of antiviral protease inhibitors for the treatment of HIV infection and AIDS. Narhex raised $8M and floated on the ASX on 12th January 2005. It still has over $6.5M in cash reserves, which it will use to perform further clinical trials and commercialise the technology.


Nar DG 35 prodrug is the first of their compounds to be selected for clinical development and has completed pre-clinical testing in animals & and Phase I and early Phase II clinical trials in humans.


We believe Narhex had a good year in 2005 in developing the drug further but poor share price performance due to lack of liquidity more than anything. The start of further clinical trials in early 2006, as announced to the ASX yesterday, has the potential to greatly increase the profile, and thus the share price, of Narhex if successful.


The announcement made yesterday said... "the purpose of the study is to test an improved formulation of DG17 which they believe will increase the extent and reliability of its absorption. The study should be completed and the data analyzed and available by end March 2006, although some interim data from the first phase of the study may be available earlier."





Link to comment
Share on other sites

In reply to: xmagx on Thursday 12/01/06 03:19pm

Hmmm. I wondered what kicked this into gear today. I thought yesterday's announcement was positive, particualry given the short timeframe until we learn some news.


I've always liked this stock, buying in at the float and topping up quite big last year. I was just thinking about buying some more..... but it looks like the cat's out of the bag. http://www.sharescene.com/html/emoticons/wink.gif

Link to comment
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now

  • Create New...